POLYPEPTIDE GROUP AG/ CH1110760852 /
- - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
-USD | - | 995 Turnover: - |
-Bid Size: - | -Ask Size: - | 1.16 bill.USD | - | - |
Business description
PolyPeptide Group is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world.
Management board & Supervisory board
CEO |
---|
Juan José Gonzalez |
Management board |
Marc Augustin, Christina Del Vecchio, Jens Fricke |
Supervisory board |
Peter Wilden, Patrick Aebischer, Beat In-Albon, Jane Salik, Erik Schropp, Philippe A. Weber |
Company data
Name: | POLYPEPTIDE N |
Address: | Neuhofstrasse 24,Baar |
Phone: | +41 435 020 580 |
Fax: | - |
E-mail: | - |
Internet: | https://www.polypeptide.com/ |
Industry: | Healthcare |
Sector: | Medical Products |
Sub sector: | Advanced Medical Devices |
End of financial year: | 12-31 |
Free Float: | 40.37% |
IPO date: | 2021-04-29 |
Investor relations
Name: | Michael Stäheli |
IR phone: | +41 435 020 580 |
IR Fax: | - |
IR e-mail: | investorrelations@po...ide.com investorrelations@polypeptide.com |
Company calendar
CW 11 | 2025-03-11 4th Quarter/Annual Report |
CW 15 | 2025-04-09 General Shareholder Meeting |
CW 33 | 2025-08-12 Interim Report 2nd Quarter/6 Months |
CW 11 | 2026-03-12 4th Quarter/Annual Report |
CW 15 | 2026-04-08 General Shareholder Meeting |
Main Shareholders
Cryosphere Foundation | 56.10% | |
Others | 27.28% | |
Premier Fund Managers Limited | 5.17% | |
Premier Portfolio Managers Limited | 4.93% | |
Rudolf Maag | 3.32% | |
PRIMECAP Management Company | 3.20% |